This episode features Dr. Nikolaos Papadantonakis from the Winship Cancer Institute of Emory University and Dr. Amer Zeidan from the Yale School of Medicine, discussing research on Myelodysplastic Syndromes (MDS) presented at the 2025 European Hematology Association (EHA) Congress in Milan.

Dr. Moshe Mittelman is hosting the world-leading expert Dr. Michael Savona and they have an attractive conversation on several mechanisms involved in the pathogenesis of MDS, including the interaction between genetics, inflammation and aging.   

Prof. Uwe Platzbecker from Leipzig and Prof. Moshe Mittelman from Tel-Aviv in an interesting conversation on the various available therapeutic modalities for patients with lower-risk MDS.

Prof. Nicolaus Kröger from Hamburg and Prof. Moshe Mittelman from Tel-Aviv, in a stimulating conversation on the various therapeutic modalities, including hematopoietic transplantation, in patients with higher-risk MDS.

Dr. Nicolaos Papadantonakis from Emory Atlanta and Dr. Moshe Mittelman from Tel-Aviv, describe several updated abstracts from 2023 ASH with a special focus on Higher-risk MDs, and providing their take home messages.

Drs Nikolaos Papadantonakis of Emory, Atlanta, US, and Moshe Mittelman, Tel-Aviv, Israel, discuss trials presented in American Society of Hematology (ASH) 2023 meeting. They provide some data on luspatercept, imetelstat, roxodustat and Ker-050.

Prof. Rena Buckstein from Toronto, and Prof. Moshe Mittelman from Tel-Aviv discuss issues related to RBC transfusions, the hemoglobin threshold for transfusion and related quality of life issues.

Prof. Akiko Shimamura of Harvard Medical School, Boston, a world known expert of pediatric hematology discusses with Prof. Guillermo Sanz ,of Valencia and Prof. Moshe Mittelman, of Tel Aviv, the various aspects of bone marrow failure including childhood MDS, the differences of this medical problem between adults and children, the unique approach to sick kids and the increasing number of promising therapeutic options.

Drs. Rafael Bejar (San Diego) and Moshe Mittelman (Tel Aviv) discuss several papers highlighting the role of genetics in MDS diagnosis, follow up and prediction of treatment. They also discuss the role of the newly approved luspatercept in the treatment of anemic transfusion-dependent patients with lower-risk MDS

Drs. Moshe Mittelman, of The Tel Aviv Sourasky Medical Center, and Drorit
Merkel, of the Sheba Medical Center, both from Tel Aviv University, Israel,
discuss several important presentations from the recent 2021 ASH meeting.
They focus on the new IPSS-M classification, discuss the approach to the
MDS patient who is currently defined by IPSS/R as belonging to the /lower-
risk group but in fact the disease behaves like a higher-risk. Finally, they
discuss issues regarding the treatment of patients with HR-MDS: What can be
added to hypomethylating agents ? Targeted therapy with IDH1/2 inhibition
and more…